CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
57.33
-2.67 (-4.45%)
At close: Mar 5, 2026, 4:00 PM EST
57.32
-0.01 (-0.02%)
After-hours: Mar 5, 2026, 6:14 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 70, with a low estimate of 44 and a high estimate of 105. The average target predicts an increase of 22.10% from the current stock price of 57.33.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 6 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 6 | 6 | 7 | 7 | 7 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 19 | 19 | 20 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $74 → $76 | Strong Buy | Maintains | $74 → $76 | +32.57% | Feb 17, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $40 → $45 | Hold | Maintains | $40 → $45 | -21.51% | Feb 13, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $62 → $74 | Buy | Maintains | $62 → $74 | +29.08% | Feb 13, 2026 |
| Needham | Needham | Strong Buy Maintains $80 → $82 | Strong Buy | Maintains | $80 → $82 | +43.03% | Feb 13, 2026 |
| Citizens | Citizens | Buy Maintains $86 → $80 | Buy | Maintains | $86 → $80 | +39.54% | Jan 30, 2026 |
Financial Forecast
Revenue This Year
59.78M
from 3.51M
Increased by 1,603.19%
Revenue Next Year
106.86M
from 59.78M
Increased by 78.75%
EPS This Year
-4.07
from -6.47
EPS Next Year
-3.33
from -4.07
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 263.3M | 264.1M | |||
| Avg | 59.8M | 106.9M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 7,400.6% | 341.7% | |||
| Avg | 1,603.2% | 78.7% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.76 | 5.05 | |||
| Avg | -4.07 | -3.33 | |||
| Low | -6.10 | -6.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.